Streetbeat News

AWKNF

Awakn Life Sciences Corp

Industry

Research and Development in Biotechnology

Open

0.09

Mkt cap

3.5M

Volume

52K

High

0.09

P/E Ratio

-1.42

52-wk high

0.19

Low

0.09

Div yield

N/A

52-wk low

0.05

Awakn Life Sciences Corp. (OTC:AWKNF) is moving closer to a Phase III clinical trial for the use of ketamine-assisted therapy to treat severe Alcohol Use Disorder (AUD). The company has also recently divested clinic assets in the UK to focus more on therapeutic research and intellectual property. The Phase III trial, which is the only one of its kind to receive government funding, will involve 280 participants and will be the largest of its kind.

Portfolio Pulse from The Dales Report

July 26, 2023 | 6:27 pm

Australia has become the first country to allow physicians to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression. In the US, lawmakers are seeking to advance drug policy changes as part of the National Defense Authorization Act (NDAA), including medical cannabis access for military veterans. The American Medical Association (AMA) has published language concerning the recently-approved Current Procedural Terminology (CPT) III codes applying to psychedelic-assisted therapies. COMPASS Pathways secured up to $50 million in a new term loan facility with Hercules Capital. AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, July 10 at $2.03, improving from prior Monday 3’s opening at $1.89.

Portfolio Pulse from Lara Goldstein

July 11, 2023 | 3:25 pm

Awakn Life Sciences Corp. (OTCQB:AWKNF) has sold its London subsidiary and healthcare clinic to a joint venture named Awakn Via Amitis Ltd., co-owned by UK mental healthcare charity Via and private UK investment company Amitis Group. The clinic will continue to operate under its original name, with Via taking over clinical operations. Awakn is also reviewing its Norwegian clinic’s business for a potential sale.

Portfolio Pulse from Lara Goldstein

July 05, 2023 | 5:54 pm

A bipartisan bill has created a $75 million research grant program for the potential treatment of mental health conditions in active duty military members. The Multidisciplinary Association for Psychedelic Studies (MAPS) announced its final agenda for its upcoming event, which will include information on two recently-identified lead compounds. Psychedelics were featured on Anderson Cooper’s CNN show. Several companies, including Silo Pharma, Clearmind, and SciSparc, are developing treatments using psychedelics. The AdvisorShares Psychedelics ETF (PSIL) showed an uptrend.

Portfolio Pulse from Lara Goldstein

July 03, 2023 | 9:01 pm

Awakn Life Sciences Corp. (OTCQB:AWKNF) has closed the second tranche of its non-brokered private placement and upsized the original financing option to $4 million. The company is focusing on the R&D of novel therapeutics and IP licensing for addiction treatments, particularly Alcohol Use Disorder.

Portfolio Pulse from Lara Goldstein

June 16, 2023 | 12:17 am

Awakn Life Sciences Corp. (OTCQB:AWKNF) is exiting ketamine healthcare services to focus on R&D of addiction therapies and IP licensing. The company has signed a non-binding term sheet to license its healthcare services IP and Kare protocol in the UK. Awakn is also reviewing its Norwegian healthcare clinics business unit and restructuring its UK clinics.

Portfolio Pulse from Lara Goldstein

June 12, 2023 | 7:18 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.